Status of vaccine research and development for Helicobacter pylori.

Status of vaccine research and development for Helicobacter pylori.
复制标题

DOI:
10.1016/j.vaccine.2018.01.001
复制
发表时间:
2019-11-28
期刊:
影响因子:
5.5
通讯作者:
Boag JM
Boag JM
中科院分区:
医学3区
文献类型:
--
作者:
Sutton P;Boag JM

文献摘要

参考文献

被引文献

相似文献

胃腺癌是全球第三大恶性肿瘤死亡原因,其中大部分疾病负担发生在低收入和中等收入国家(LMIC),尤其是亚洲。这些癌症中的大多数是由于慢性胃炎引起的,慢性胃炎是由胃内细菌幽门螺杆菌感染引起的。因此,针对这种病原体的疫苗将是预防胃腺癌的有力工具。然而,尽管疫苗接种可以保护儿童免受H。幽门螺杆菌感染,目前没有先进的候选疫苗,只有一种疫苗在I期临床试验中。此外,研制抗H.尽管全球疾病负担很大,但幽门螺杆菌不是主要制药公司当前的战略重点。考虑到这些公司的参与可能对后期发展至关重要,因此有必要提高对LMIC中这种疾病负担的认识,并增加投资以重振H.幽门螺杆菌疫苗研究与开发
Gastric adenocarcinoma is globally the third leading cause of death due to malignancy, with the bulk of this disease burden being suffered by low and middle income countries (LMIC), especially in Asia. The majority of these cancers develop as a result of a chronic gastritis that arises in response to infection with the stomach-dwelling bacterium, Helicobacter pylori. A vaccine against this pathogen would therefore be a powerful tool for preventing gastric adenocarcinoma. However, notwithstanding a proof-of-concept that vaccination can protect children from acquisition of H. pylori infection, there are currently no advanced vaccine candidates with only a single vaccine in Phase I clinical trial. Further, the development of a vaccine against H. pylori is not a current strategic priority of major pharmaceutical companies despite the large global disease burden. Given the involvement of such companies is likely to be critical for late stage development, there is therefore a need for an increased appreciation of the burden of this disease in LMIC and more investment to reinvigorate research in H. pylori vaccine Research and Development.
DOI: 10.1136/gut.2007.145839
发表时间: 2008-08
期刊: Gut
影响因子: 24.5
作者:
Aebischer T;Bumann D;Epple HJ;Metzger W;Schneider T;Cherepnev G;Walduck AK;Kunkel D;Moos V;Loddenkemper C;Jiadze I;Panasyuk M;Stolte M;Graham DY;Zeitz M;Meyer TF
通讯作者: Meyer TF
在中国和美国幽门螺杆菌感染流行的时间趋势的系统综述。
DOI: 10.1186/s13099-016-0091-7
发表时间: 2016
期刊: Gut pathogens
影响因子: 4.2
作者:
Nagy P;Johansson S;Molloy-Bland M
通讯作者: Molloy-Bland M
DOI: 10.1136/gut.2003.037499
发表时间: 2004-09-01
期刊: GUT
影响因子: 24.5
作者:
Graham, DY;Opekun, AR;Monath, TP
通讯作者: Monath, TP
由霍乱毒素 B 单元和幽门螺杆菌 Lpp20 表位组成的表位疫苗诱导的抗体产生和 Th1 偏向反应
DOI: 10.1111/hel.12268
发表时间: 2016-06-01
期刊: HELICOBACTER
影响因子: 4.4
作者:
Li, Yan;Chen, Zhongbiao;Ning, Yunshan
通讯作者: Ning, Yunshan
DOI: 10.1086/515105
发表时间: 1999-02-01
影响因子: 11.8
作者:
Malaty, HM;Graham, DY;Berenson, GS
通讯作者: Berenson, GS